Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.
2.

JNK inhibition as a potential strategy in treating Parkinson's disease.

Wang W, Ma C, Mao Z, Li M.

Drug News Perspect. 2004 Dec;17(10):646-54. Review.

PMID:
15696229
3.

Mitogen-activated protein kinase kinase 4 (MKK4).

Cuenda A.

Int J Biochem Cell Biol. 2000 Jun;32(6):581-7. Review.

PMID:
10785355
4.

Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential.

Bogoyevitch MA, Boehm I, Oakley A, Ketterman AJ, Barr RK.

Biochim Biophys Acta. 2004 Mar 11;1697(1-2):89-101. Review.

PMID:
15023353
5.
6.

Physiological roles of MKK4 and MKK7: insights from animal models.

Wang X, Destrument A, Tournier C.

Biochim Biophys Acta. 2007 Aug;1773(8):1349-57. Epub 2006 Nov 10. Review.

7.

Agents targeting c-Jun N-terminal kinase pathway as potential neuroprotectants.

Zhang GY, Zhang QG.

Expert Opin Investig Drugs. 2005 Nov;14(11):1373-83. Review.

PMID:
16255677
8.

MKK4 and metastasis suppression: a marriage of signal transduction and metastasis research.

Robinson VL, Hickson JA, Vander Griend DJ, Dubauskas Z, Rinker-Schaeffer CW.

Clin Exp Metastasis. 2003;20(1):25-30. Review.

PMID:
12650604
9.

Tipping Points and Endogenous Determinants of Nigrostriatal Degeneration by MPTP.

Schildknecht S, Di Monte DA, Pape R, Tieu K, Leist M.

Trends Pharmacol Sci. 2017 Jun;38(6):541-555. doi: 10.1016/j.tips.2017.03.010. Epub 2017 Apr 23. Review.

PMID:
28442167
10.

Activation of JNK pathway in persistent pain.

Gao YJ, Ji RR.

Neurosci Lett. 2008 Jun 6;437(3):180-3. doi: 10.1016/j.neulet.2008.03.017. Epub 2008 Mar 13. Review.

Supplemental Content

Support Center